Free Trial

Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Quadrature Capital Ltd

Illumina logo with Medical background

Quadrature Capital Ltd lowered its stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 82.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,490 shares of the life sciences company's stock after selling 128,299 shares during the quarter. Quadrature Capital Ltd's holdings in Illumina were worth $3,454,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently added to or reduced their stakes in the company. Industrial Alliance Investment Management Inc. bought a new stake in Illumina during the second quarter valued at about $34,000. Massmutual Trust Co. FSB ADV raised its stake in Illumina by 65.1% in the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company's stock valued at $56,000 after buying an additional 168 shares during the last quarter. Private Trust Co. NA raised its stake in Illumina by 81.2% in the third quarter. Private Trust Co. NA now owns 473 shares of the life sciences company's stock valued at $62,000 after buying an additional 212 shares during the last quarter. Focused Wealth Management Inc purchased a new stake in Illumina in the third quarter valued at about $63,000. Finally, Hollencrest Capital Management purchased a new stake in Illumina in the third quarter valued at about $63,000. Institutional investors own 89.42% of the company's stock.

Illumina Price Performance

ILMN traded up $1.18 during trading on Friday, hitting $141.09. The company's stock had a trading volume of 1,106,672 shares, compared to its average volume of 2,015,189. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94. Illumina, Inc. has a twelve month low of $100.08 and a twelve month high of $156.66. The business's fifty day simple moving average is $142.90 and its 200 day simple moving average is $126.66. The firm has a market capitalization of $22.38 billion, a price-to-earnings ratio of -14.17 and a beta of 1.11.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, beating the consensus estimate of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The company had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. During the same period last year, the company earned $0.33 earnings per share. Illumina's quarterly revenue was down 3.5% compared to the same quarter last year. On average, equities research analysts forecast that Illumina, Inc. will post 4.11 EPS for the current fiscal year.

Analysts Set New Price Targets

ILMN has been the subject of a number of research analyst reports. UBS Group increased their price target on Illumina from $133.00 to $145.00 and gave the company a "neutral" rating in a research note on Tuesday, November 5th. Canaccord Genuity Group increased their price target on Illumina from $130.00 to $145.00 and gave the company a "hold" rating in a research note on Tuesday, November 5th. Citigroup increased their price target on Illumina from $155.00 to $190.00 and gave the company a "buy" rating in a research note on Tuesday, November 5th. Hsbc Global Res upgraded Illumina from a "hold" rating to a "strong-buy" rating and set a $180.00 price target for the company in a research note on Thursday, October 17th. Finally, Robert W. Baird raised their price objective on Illumina from $124.00 to $139.00 and gave the stock a "neutral" rating in a research note on Wednesday, November 6th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have assigned a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $164.00.

Read Our Latest Stock Report on Illumina

Illumina Company Profile

(Free Report)

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Recommended Stories

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

→ Most People Are Dead Wrong. (From Brownstone Research) (Ad)

Should you invest $1,000 in Illumina right now?

Before you consider Illumina, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.

While Illumina currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

The Future of Healthcare: 3 AI Stocks Leading the Way
Analysts Predict Big Gains for These 3 Cybersecurity Leaders
This Investment Strategy Has the Highest Payout Potential

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines